Moderna (MRNA) Other financing activities (2018 - 2026)

Moderna (MRNA) has 9 years of Other financing activities data on file, last reported at $19.0 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 533.33% year-over-year to $19.0 million in Q1 2026; TTM through Mar 2026 was $51.0 million, a 5.56% decrease from a year earlier, with the FY2025 full-year figure at $35.0 million, down 46.97% from the prior year.
• Other financing activities for Q1 2026 stood at $19.0 million, up from $16.0 million in the prior quarter.
• Over the last five years, Other financing activities for MRNA reached as high as $32.0 million in Q2 2024 and fell as low as $2.0 million in Q3 2025.
• Historically, Other financing activities has averaged $13.6 million across 5 years, with a median of $14.0 million in 2025.
• Across the five-year window, Other financing activities tumbled 80.0% in 2025 and jumped 533.33% in 2026, its largest moves.
• Year by year, Other financing activities stood at $25.0 million in 2022, then sank by 40.0% to $15.0 million in 2023, then decreased by 26.67% to $11.0 million in 2024, then soared by 45.45% to $16.0 million in 2025, then increased by 18.75% to $19.0 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $19.0 million in Q1 2026, $16.0 million in Q4 2025, and $2.0 million in Q3 2025.